• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Brimonidine-timolol gets good results, study shows


Pooled results from two randomized, investigator-masked parallel group clinical trials show that the fixed combination of 0.2% brimonidine-0.5% timolol produced greater IOP lowering than the fixed combination of 0.2% dorzolamide-0.5% timolol, whether the fixed combination products were used alone or as an adjunct to existing treatment with a prostaglandin analogue.

Dr. Nixon is director, Trimed Eye Center, Barrie, Ontario, and the lead author of the published paper reporting the study results.1 The studies included 180 adult patients with open angle glaucoma or ocular hypertension enrolled at 10 investigational sites. Participants could be either naïve to previous treatment or in need of further IOP lowering on existing therapy, and they were randomly assigned to B.I.D. treatment with one of the two fixed combination products. IOP measurements were obtained at peak effect (10 a.m.), and the primary efficacy analysis was based on mean change in IOP after 3 months.

The role of adjunctive therapy

"Although numerically the difference in IOP lowering between fixed-combination treatment groups was even greater in the adjunctive therapy subgroup versus the monotherapy subgroup, there were fewer adjunctive therapy patients. Therefore, this study may not have had sufficient power to detect a statistically significant difference between the two adjunctive treatment groups," Dr. Nixon observed.

"However, in a previous review by Anne Coleman, MD,2 she felt that an effective adjunctive therapy should provide at least 15% to 20% further lowering of IOP. On that basis, the 29% reduction achieved with brimonidine-timolol indicates it is an excellent choice for adjunctive therapy, which also is the most common role for use of a fixed combination product," he said.

There were no significant differences between treatment groups in their baseline characteristics. Overall, the study population had an average age of about 68 years, was predominantly Caucasian (92%), female (56%), and had a diagnosis of open-angle glaucoma (~85%). A majority of patients (56%) was treated with the fixed combination product as monotherapy, and about 70% of those patients used it as a substitute for prior therapy. Within the adjunctive treatment subset, there were no significant differences between the two fixed combination groups with respect to use of the various prostaglandin analogues.

There also were no statistically significant differences between treatment groups in baseline IOP. For the monotherapy patients, mean baseline IOP was 23.0 mm Hg in the brimonidine-timolol group and 23.6 mm Hg in the dorzolamide-timolol group. Corresponding values in the adjunctive treatment group were 21.9 and 21.0 mm Hg, respectively.

Comfort ratings

The study also investigated comfort and tolerability using a questionnaire administered after 1 month. Patients using brimonidine-timolol reported significantly less burning, stinging, and unusual taste compared with the group treated with dorzolamide-timolol (p <0.001 for all comparisons). For all of these adverse effects, mean scores were <1.0 (very minimal) in the brimonidine-timolol group and ranged between 1.2 and ~2 (mild) in the dorzolamide-timolol group.

"Overall comfort ratings also showed a statistically significant difference favoring brimonidine-timolol with the proportion of patients rating their study treatment as 'very comfortable' being about twofold higher in the brimonidine-timolol group compared with the dorzolamide-timolol users, 41% versus 21%," Dr. Nixon noted.

"The better safety profile of brimonidine-timolol in this study has implications for medication compliance, which remains one of the biggest obstacles in management of ocular hypertension and glaucoma. Perhaps greater comfort might have resulted in increased compliance for patients in the brimonidine-timolol group, which could have contributed to its greater IOP-lowering effects," he said.

A post-hoc analysis of the study data, conducted by Eve Higginbotham, MD, investigated incremental cost-effectiveness of the two fixed combinations. The results showed that the proportion of patients achieving IOP thresholds between <12 mm Hg and <17 mm Hg was consistently about 20% higher in the brimonidine-timolol group compared with the dorzolamide-timolol group, resulting in a statistically significant incremental benefit for the brimonidine-timolol group within that IOP range.


1. Nixon DR, Yan DB, Chartrand JP, Piedmonts RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009;25:1645-1653.

2. Coleman AL, Baerveldt G, Bournias TE. In: Managing Glaucoma: The Current Clinical Strategies. 2003.

Related Videos
Jacobi Cleaver, OD, FAAO
Jade Coats, OD, overviews a lecture on ocular pain and patient care
Jade Coats, OD, outlines two poster presentations she gave on a novel lipid-containing eye drop at the AOA Optometry's Meeting
Adam Alexander, OD, chats with Optometry Times about his AOA e-poster presentation on Miebo
Lorraine Provencher, MD, presenting slides
Megan Cavet, PhD
Nazlee Zebardast, MD, MSc, overviews her ARVO 2024 presentations on glaucoma and polygenic risk scores
© 2024 MJH Life Sciences

All rights reserved.